5. Net Income/(Loss) Per Share The following table sets forth the computation of basic and diluted net income/ (loss) per share for the years ended December 31, 2022 and 2021 (in thousands, except number of shares and per share amounts): | | | | | | | | | Year ended | | Year ended | | | December 31, | | December 31, | Numerator: | | 2022 | | 2021 | Net income/ (loss) | | $ | 5,321 | | $ | (51,112) | Net loss attributable to noncontrolling interest | | | 21 | | | 247 | Net income/ (loss) attributable to Vaccitech shareholders | | $ | 5,342 | | $ | (50,865) | Denominator: | | | | | | | Weighted-average ordinary shares outstanding, basic | | | 37,248,126 | | | 25,894,375 | Effect of dilutive stock options | | | 921,181 | | | — | Weighted-average ordinary shares outstanding, diluted | | | 38,169,307 | | | 25,894,375 | Net income/ (loss) per share attributable to ordinary shareholders, basic | | $ | 0.14 | | $ | (1.96) | Net income/ (loss) per share attributable to ordinary shareholders, diluted | | $ | 0.14 | | $ | (1.96) |
Potential ordinary shares issuable for stock options that are excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact are as follows: | | | | | | | Year ended | | Year ended | | | December 31, | | December 31, | | | 2022 | | 2021 | Stock options | | 2,912,756 | | 2,604,969 |
|